What ipamorelin is
Ipamorelin is a pentapeptide that activates the ghrelin receptor, prompting the pituitary to release growth hormone. Its distinguishing pharmacological feature is selectivity: unlike some earlier growth hormone secretagogues, it produces relatively little increase in prolactin, cortisol or ACTH.
That selectivity was the point of developing it, and it is a genuine property, not marketing.
The most informative fact about ipamorelin
Ipamorelin was developed by Novo Nordisk. It entered human trials, including work in postoperative ileus — the temporary shutdown of gut motility after abdominal surgery, where a ghrelin agonist has a plausible rationale.
Development was discontinued.
A pharmaceutical company that owns a compound, has invested in taking it into human trials, and then stops, has usually learned something. The absence of a licensed ipamorelin product is itself a data point.
Companies discontinue programmes for many reasons — insufficient efficacy, commercial priorities, portfolio decisions. But the practical consequence is the same: there is no modern, well-powered, published human trial programme demonstrating that ipamorelin does anything clinically useful.
What is actually being sold
Ipamorelin is marketed for body composition, recovery, sleep quality and anti-ageing. None of these were established in the development programme, and no independent trial programme has established them since.
It is also very commonly sold as a blend with CJC-1295 — a combination which has no trial literature at all. Two compounds without individual efficacy evidence do not produce combined evidence.
What raising growth hormone involves
Stimulating the growth hormone axis is not inherently benign. Growth hormone opposes insulin action and can worsen glucose handling. Fluid retention, joint pain and carpal tunnel symptoms are recognised effects of GH axis stimulation. IGF-1 is a proliferative signal, and sustained elevation in people without a deficiency has not been established as safe.
Licensed drugs acting on this axis carry IGF-1 monitoring requirements for these reasons.
Ghrelin receptor agonism also stimulates appetite, which is a predictable consequence of the mechanism and frequently underplayed.
Purity and identity problems
Growth hormone secretagogues are among the most commonly mislabelled products in the grey peptide market. Short peptides are relatively cheap to synthesise badly, the buyer has no way to verify what arrived, and subjective effects are easily attributed to a product regardless of its contents.
Regulatory position
Ipamorelin holds no marketing authorisation anywhere in the world. It is not an approved medicine in any country and cannot be lawfully supplied for human use in the UK.
Where this leaves you
Ipamorelin is real pharmacology with a clean receptor profile and an abandoned development programme. What exists is a well-understood mechanism and no demonstrated clinical benefit — a combination the grey market has been selling successfully for well over a decade.